Abstract Details

Title Delayed malignant cerebellar posterior reversible encephalopathy syndrome secondary to (CLAG-M) and venetoclax regimen.

Topic Neuro-oncology

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 11-006

Objective PRES (posterior reversible encephalopathy syndrome) is a heterogenous syndrome caused by multiple factors. Cerebellar PRES is commonly seen with autoimmune disease and rarely with chemotherapy.

Background Isolated cerebellar malignant posterior reversible encephalopathy syndrome (PRES) is rare. We report a case of delayed malignant cerebellar PRES triggered by cladribine, cytarabine, granulocyte colony-stimulating factor, mitoxantrone (CLAG-M) and venetoclax regimen.

Design/Methods A 73-year-old male presented with history of relapse after allogeneic stem cell transplantation for refractory myelodysplastic syndrome on maintenance tacrolimus. He was admitted for salvage therapy with (CLAG-M) + venetoclax regimen. Day 16^th post salvage therapy he developed acute onset altered mental status and headache followed by fever and hypotension. Brain MRI revealed posterior bilateral cerebellar, vermian edema with tiny petechial hemorrhages, ventriculomegaly, transependymal edema and mass effect on fourth ventricular effacement. Despite external ventricular drain placement, hyperosmolar therapy and steroids, day 19^ththe patient suffered devastating neurological injury and family opted for hospice care. Of note, maintenance tacrolimus was held prior to admission and was started 4 days prior to onset of neurological symptoms with sub-therapeutic levels.

Results NA

Conclusions

The potential role of (CLAG-M) and venetoclax regimen in the pathogenesis of PRES needs to be considered. Cerebellar PRES is rare and can be complicated by early hydrocephalus and 4^th ventricle compression. Although PRES is usually benign, prompt recognition of indicators of the malignant phenotype and aggressive management is crucial.

Authors/Disclosures
Isha Snehal, MBBS PRESENTER	Dr. Snehal has nothing to disclose.
Subin Mathew, MD	Dr. Mathew has nothing to disclose.

��ɫ��

��ɫ��